4//SEC Filing
OSBORNE DAVID W 4
Accession 0001567619-22-006492
CIK 0001787306other
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 8:47 PM ET
Size
11.7 KB
Accession
0001567619-22-006492
Insider Transaction Report
Form 4
OSBORNE DAVID W
Chief Technical Officer
Transactions
- Award
Common Stock
2022-03-03+13,300→ 260,282 total - Sale
Common Stock
2022-03-04$16.86/sh−828$13,959→ 259,454 total - Sale
Common Stock
2022-03-07$16.44/sh−28$460→ 259,426 total - Award
Stock Option (Right to Buy)
2022-03-03+35,300→ 35,300 totalExercise: $17.67Exp: 2032-03-03→ Common Stock (35,300 underlying)
Footnotes (6)
- [F1]Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2023, subject to the Reporting Person's continued service to the Issuer.
- [F2]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs").
- [F3]The transaction was executed in multiple trades in prices ranging from $16.63 to $17.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The transaction was executed in multiple trades in prices ranging from $16.44 to $16.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F5]Includes 24,925 RSUs.
- [F6]1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.
Documents
Issuer
Arcutis Biotherapeutics, Inc.
CIK 0001787306
Entity typeother
Related Parties
1- filerCIK 0001252999
Filing Metadata
- Form type
- 4
- Filed
- Mar 6, 7:00 PM ET
- Accepted
- Mar 7, 8:47 PM ET
- Size
- 11.7 KB